Vaxine thanks the support of all Australians who have contributed to our campaign to make our protein-based Covax-19 vaccine available in Australia.
Our vaccine is the first synthetic protein vaccine against Covid-19 to receive market authorisation, after showing protection against the Delta virus variant in a Phase 3 clinical trial in 16,876 subjects in Iran.
It remains the first and only successful Southern hemisphere-developed Covid-19 vaccine .
As a small Australian research group, these valuable funds are being used to support development of our vaccines.
Having reached our target, we have deactivated the ability to subscribe and the plan will be to now take down this campaign page.